General Meeting results

EDX Medical Group PLC

25 October 2023

 

EDX Medical Group plc

General Meeting

October 25, 2023

Result of General Meeting

The General Meeting of EDX Medical Group plc was held at the Roosevelt Room, Brown's Hotel, Albemarle Street, London, on 25 October 2023 at 2:00 p.m.

All three resolutions put to members were passed on a poll as ordinary resolutions.

The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:

Resolution	Votes for	%	Votes against	%	Votes withheld
Resolution 1 (Ordinary) To receive the Annual Report and Accounts of the Company for the financial year ended 31 March 2023 together with the Directors' reports and auditor's report on those accounts.	149,949,300	100.00	0	0.00	0
Resolution 2 (Ordinary) To re-appoint PKF Littlejohn LLP as auditor of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company.	149,949,300	100.00	0	0.00	0
Resolution 3 (Ordinary) To authorise the Directors to determine the fees payable to the auditor.	149,949,300	100.00	0	0.00	0

As at 25 October 2023, there were 300,965,909 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

The full text of each resolution is available in the Notice of General Meeting, published on our website.

About EDX Medical Group

EDX Medical Group plc develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease and infectious diseases. The company is listed on the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical has established expertise in the design, development, validation and sourcing of diagnostic testing solutions to ISO 13485 and key laboratory tests performed by the Company have been accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

EDX Medical Group operates a molecular biology and diagnostics laboratory in Cambridge, UK, and 100%-owned subsidiary companies, Hutano Diagnostics Limited in Oxford, UK, and Torax Biosciences Ltd in Ireland. 

Learn more: www.edxmedical.co.uk.

Contacts:

EDX Medical plc
Dr Mike Hudson (Chief Executive Officer)	[phone]
Oberon Capital
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)	[phone]
Media House International
Ramsay Smith Gary McQueen	[phone] [e-mail] + 44 (0)7834 694609 [e-mail]

 

END